YKL-40 expression in anal carcinoma predicts shorter overall and disease-free survival

Histopathology

Volumn 55, Issue 2, 2009, Pages 238-240

  Castellano, Isabella ^a   Mistrangelo, Massimiliano ^a   Crudo, Valentina ^a   Chiusa, Luigi ^a   Lupo, Rosanna ^a   Ricardi, Umberto ^a   Morino, Mario ^a   Mussa, Antonio ^a   Cassoni, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ANUS CARCINOMA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; LETTER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM BIOPSY; SQUAMOUS CELL CARCINOMA;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; LECTINS; MALE; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 68749091417     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03364.x     Document Type: Letter

References (13)

1. Allal AS, Waelchli L, Brundler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin. Cancer Res. 2003 9 6489 6496.
2. Clancy R. Nitric oxide alters chondrocyte function by disrupting cytoskeletal signaling complexes. Osteoarthritis Cartilage 1999 7 399 400.
3. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem. Biophys. Res. Commun. 2001 285 926 931.
4. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 2001 60 619 626.
5. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sorensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J. Infect. Dis. 1999 180 1722 1726.
6. Volck B, Price PA, Johansen JS et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians 1998 110 351 360.
7. Roslind A, Johansen JS, Christensen IJ et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int. J. Cancer 2008 122 857 863.
8. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br. J. Cancer 1999 79 1494 1499.
9. Hogdall EV, Johansen JS, Kjaer SK et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol. Rep. 2003 10 1535 1538.
10. Dehn H, Hogdall EV, Johansen JS et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet. Gynecol. Scand. 2003 82 287 293.
11. Johansen JS, Christensen IJ, Riisbro R et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res. Treat. 2003 80 15 21.
12. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 2003 9 4423 4434.
13. Pelloski CE, Mahajan A, Maor M et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 2005 11 3326 3334.